Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
4,803 total articles
Datadog has taken a hit from the AI-driven software rotation, but its platform remains central to enterprise operations. With a $45B market cap, $1.0B in free cash flow and a series of AI-focused partnerships, the stock looks like an actionable upgrade trade. We lay out entry, stop, target and the catalysts that could re-rate the multiple.
D-Wave has begun to prove its go-to-market story: triple-digit revenue growth, a string of meaningful bookings and a large customer win. The balance sheet and recent acquisition give the company optionality while the stock's retreat compresses downside for patient, risk-aware traders. This trade idea lays out a long entry, stop, targets and the cat…
Cisco trades at roughly $307.7B market cap, ~27x earnings and an EV/EBITDA of 21.3 despite low-single-digit free cash flow yield and a mature networking business. Technicals show weakening momentum and short activity is elevated. This is a tactical short idea with a clear entry at $78.00, stop at $83.50 and a mid-term target of $70.00 (45 trading d…
Netskope plunged to the low $9s on heavy volume after post-IPO selling. Fundamentals show durable growth and product momentum, but GAAP losses and mixed guidance keep sentiment fragile. This trade targets a mid-term rebound off oversold technicals and crowded short positioning.
monday.com plunged from its 2025 highs and now trades at a valuation that assumes meaningful deceleration. I view the sell-off as a tactical buying opportunity for disciplined, mid-term traders who accept company-specific and AI-related execution risk. Entry $75.00, target $128.00, stop $66.00; horizon: mid term (45 trading days).
Dollar General pulled back sharply after conservative fiscal-2026 guidance, but the underlying economics remain attractive: solid free cash flow ($2.34B), steady EPS ($5.80 trailing), and a resilient business model as consumers trade down. This trade idea is a mid-term swing buy on weakness with a clear entry, stop and target.
Iridium (IRDM) has jumped from last year's lows and is trading well above several moving averages. Fundamentals remain solid — free cash flow near $300M and a healthy ROE — but leverage, a high price/book, and an RSI flirting with overbought levels argue the rally is vulnerable. We lay out an actionable short with a clear entry, stop and target for…
Edgewell Personal Care (EPC) trades at an undemanding valuation (market cap ~$895M, EV/EBITDA ~9.5) after divesting its feminine care business. With steady free cash flow, a 3% dividend, and clear cost-money levers, the stock offers a risk-reward profile worth a tactical long. Entry $19.15, target $26.00, stop $17.00; horizon: long term (180 tradin…
With crude north of $100 after geopolitical disruption in the Middle East and meaningful stagflation concerns for equities, Tourmaline Oil looks like a deep-value candidate where optionality on higher commodity prices and operational resilience can produce a quick, asymmetric payoff. This is a tactical long idea with a concrete entry at $5.50, stop…
We upgrade Rocket Lab (RKLB) to Buy after the company’s strategic reset and a string of operational wins. Q4 strength, a $1.85 billion backlog, $2.48 billion in cash, and growing defense revenue (including repeat hypersonic missions) create a reasonable risk/reward for a long trade. The stock remains richly valued, so position sizing and a discipli…
Amgen's recent rally looks fundamentally supported by optimism around MariTide's once‑monthly obesity program and better‑than‑feared osteoporosis performance. The company trades at ~$370 with a market cap near $199.5B, generates roughly $8.1B in free cash flow and carries a P/E ~26.5. This trade idea is a mid‑term long: enter at $370.08, target $39…
Rheinmetall is a direct play on a defense upgrade cycle that is expanding beyond ammunition and armored vehicles into high-margin sensors and electronics. With hyperspectral imaging markets forecast to double from $0.92B in 2025 to $1.83B by 2030 (CAGR 14.7%), Rheinmetall's push into sensors, electro-optics, and integrated platform upgrades gives i…
Lumentum's optics business is moving from quiet growth to visible AI-infrastructure demand. Recent news - including an Nvidia-backed investment and upcoming S&P 500 inclusion - should tighten supply/demand in the near term. The stock is richly valued on history, but the trade offers a defined risk-reward if you buy the narrative and the catalysts p…
Novo Nordisk is priced like a company that has lost its core franchise. The market reaction has created a high-conviction, asymmetric trade: buy Novo at current levels to capture upside from renewed distribution (Hims & Hers), product life-cycle catalysts and a recovery in investor sentiment. Entry at $38.40, stop $35.00, target $60.00, horizon: lo…
Broadcom is morphing from a diversified semiconductor and software supplier into a high-cash-flow AI infrastructure powerhouse. With custom AI ASICs and next-gen optical DSPs ramping, free cash flow of roughly $26.9B and a fortress balance sheet, the stock merits a long trade with a $400 target and a $295 stop. Valuation is rich, but execution and …
Unusual Machines (UMAC) is transitioning from growth story to execution. After doubling 2025 revenue to $11.2M and signalling positive operating cash flow by year-end 2026, the company has the balance sheet and exposure to domestic defense demand to scale. We upgrade to Buy and lay out a disciplined entry at $20.00, stop at $16.50 and a $35.00 targ…
Henry Schein ($HSIC) looks attractively priced relative to cash flow and peers in medical distribution. The company's $200M efficiency plan, steady free cash flow ($573M), and expanding partnerships provide upside. However, recent margin softness in dental operations, litigation headlines, and mixed technicals argue for a controlled entry, defined …
Pixelworks is a microcap semiconductor play trading near $6 with a thin float and a recently reported cash improvement tied to Shanghai activity. Given low valuation multiples (EV/Sales ~0.76) and an existing royalty/licensing pathway, a disciplined long with a $5.90 entry, $10.00 target and $4.50 stop can capture upside if management converts the …
Netskope (NTSK) is trading near its 52-week low despite 33% sales growth and a reported 118% net retention rate. With a market cap near $3.69B, improving cash dynamics that management highlights as moving to free-cash-flow positive, and technicals showing a decent base, this is a tactical mid-term long: enter at $9.40, stop at $8.50, target $15.00 …
Nvidia's reported $2 billion deal with Nebius is a leverage point for sustained data-center demand, software monetization and higher-margin recurring revenue. The market's cool reaction leaves a tactical opportunity: a mid-term swing trade to capture re-rating if Nebius scales and Nvidia converts the deal into hardware + software attach. Entry, sto…
AeroVironment disappointed with a Q3 miss and negative cash flow, but bookings and counter-drone demand are accelerating. For traders willing to accept execution risk, a mid-term swing long on a pullback offers asymmetric upside while preserving defined risk.
ServiceNow remains the enterprise backbone for workflow automation. Recent AI integrations such as Now Assist and partnerships that harden agent resilience make it more likely customers expand rather than abandon the platform. Given strong subscription growth, $4.6B in free cash flow and low net leverage, I recommend a long trade with a 180-trading…
Eaton is delivering resilient operating performance driven by Electrical and Aerospace segments, supported by a surge in data-center orders. The shares trade at a premium (P/E ~34, market cap ~$137B) but still offer a constructive risk/reward for a disciplined mid-term long trade. Entry at $354.61 with a $338 stop and $381 target balances upside fr…
Bread Financial is trading at single-digit earnings multiples, showing early signs of credit stabilization and modest loan growth. With a market cap around $3.1B, a P/B near 1x and an improving loss picture, the risk/reward looks asymmetric for a tactical long. This trade idea lays out entry, stops, targets and the scenarios that would invalidate t…
Fulgent Genetics (FLGT) trades near cycle lows at ~$14.19 despite a technology-led testing platform, a clean balance sheet, and valuation multiples that look cheap relative to recovery scenarios. The market has punished the stock for legal inquiries and margin volatility; that reaction appears overdone. This trade idea lays out a mid-term long with…
